Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Silicon containing doai
Patent
1995-09-21
1998-05-19
MacMillan, Keith
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Silicon containing doai
514895, A01N 5510
Patent
active
057536325
DESCRIPTION:
BRIEF SUMMARY
This Application is a 371 of PCT/EP94/01056, filed Apr. 5, 1994, which claims priority to German Patents P 43 11 546.2, filed Apr. 7, 1993.
Use of colloidal silica for the treatment of sickle-cell anaemia, malaria and exogenously induced leucopenias
The invention relates to the use of colloidal silica for the treatment of sickle-cell anaemia, malaria and exogenously induced leucopenias.
The invention is based, inter alia, on the knowledge that the oral administration of silica in colloidal form can be employed advantageously for the treatment of homozygous patients having sickle-cell anaemia. Furthermore, the oral administration of silica causes a normalisation of the blood count, inter alia with stimulation of haematopoiesis (formation of blood).
Disorders of haematopoiesis can arise in many different ways; within the meaning of the invention these disorders are caused in particular by sickle-cell anaemia and by malaria. Exogenously induced leucopenias in particular arise as a consequence of the action of ionising radiations and as a result of treatment with medicaments such as cytostatics.
Sickle-cell anaemia is at present treated by blood transfusions. During this therapy, a haemolytic crisis occurs on average every three months. This consists, on the one hand, of a very severe intravascular haemolysis and moreover in a blockage of the arterioles and capillaries, which is very painful and leads to tissue damage in the downstream tissues. A significant disadvantage of this therapy is that the bodies of the patients are overloaded with iron. The life expectancy of the patients is about 30 years. In about half of the children, two to five haemolytic crises occur within two months.
Using the subject of the invention, it is possible in a controlled manner to decrease the total number of haemolytic crises in homozygous patients having sickle-cell anaemia; furthermore, disorders of haematopoiesis induced in other ways can also be eliminated and exogenously induced leucopenias treated.
The mechanism of action of silica in sickle-cell anaemia is not known. Inhibition of polymerisation of haemoglobin, which is abnormal in this disease, is possible. A stabilisation of the erythrocyte surface with the result that the formation of sickle cells stops and thus the haemolytic crises are avoided and the tissues are adequately perfused is furthermore also conceivable. Furthermore, an improvement in oxygen transport by the blood is also conceivable as a result of the buffer action of silicic acid, by means of which the intracellular pH of the erythrocytes is positively affected.
In a controlled investigation of patients ill with sickle-cell anaemia, it was possible by means of the use according to the invention considerably to decrease haemolytic crises occurring in the patients. 90% of the children still only had, at most, one crisis every two months; only 10% of the children suffered one crisis per month. By this means, it was possible drastically to decrease the number of necessary blood transfusions in the investigated group as well as the frequency of stays in hospital. The percentage of the children who either had to be admitted to hospital or received a blood transfusion two to three times within two months could be reduced from 20% to 0%. The use according to the invention simultaneously led to a clear decrease in the accompanying symptoms of sickle-cell anaemia. The extent of jaundice, enlargement of the spleen and osteomyelitis declined significantly during treatment.
For the investigations carried out the medicament was given in colloidal form; it contained 2.8% silica according to the invention; preparations of colloidal silica of this type are commercially available. According to the invention, the composition was given in a quantity of 2.times.1 tablespoons per day, dissolved or suspended in some mineral water, before meals.
The effect of the composition employed according to the invention was investigated as a function of the treatment and time, to be precise in particular with respect to
20 children with s
REFERENCES:
patent: 3753102 (1973-08-01), Beck
patent: 3813939 (1974-06-01), Head
patent: 3944354 (1976-03-01), Benwood et al.
patent: 4179934 (1979-12-01), Svarovsky
patent: 4512200 (1985-04-01), Ghering et al.
patent: 4607228 (1986-08-01), Reif
patent: 4631482 (1986-12-01), Newton et al.
patent: 4714890 (1987-12-01), Dechene et al.
patent: 4904944 (1990-02-01), Dechene et al.
patent: 5021426 (1991-06-01), Baldwin et al.
patent: 5022274 (1991-06-01), Klinzing et al.
patent: 5054325 (1991-10-01), Dechene et al.
patent: 5095275 (1992-03-01), Dechene et al.
patent: 5225200 (1993-07-01), Gribbin
patent: 5287061 (1994-02-01), Dechene et al.
patent: 5362726 (1994-11-01), Tackie et al.
patent: 5396806 (1995-03-01), Dechene et al.
Pat. Abstract of Japan vol. 011, #173 (English Language).
(Derwent) WPIDS Abstract AN66-08545F, Aug. 31, 1993 (corresponds to DE 1171432A.).
Medline Abstract 93057493 (Heishko et al. Aug. 15, 1992).
Ivanov, Z. et al., "Peripheral blood changes induced by the chronic effect of radon and silicon dioxide (in combination or separately)", Chemical Abstracts, 83:19, Nov. 10, 1975, Abstract No,159997.
Bisse Emmanuel
Schmidt Alfred
Wieland Heinrich
LandOfFree
Use of colloidal silica for the treatment of sickle-cell anaemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of colloidal silica for the treatment of sickle-cell anaemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of colloidal silica for the treatment of sickle-cell anaemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1853076